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Surveillance of high-risk individuals for pancreatic ductal adenocarcinoma (PDAC) and its precursors 
might lead to better outcomes. The aim of this study was to determine prevalence and outcomes of 
PDAC and high-risk neoplastic precursor lesions among such patients participating in surveillance 
programmes.  
Method 
A multicentre study was conducted through the International CAPS Consortium Registry to identify high 
risk individuals who had undergone pancreatic resection or progressed to advanced PDAC while under 
surveillance. High-risk neoplastic precursor lesions were defined as: pancreatic intraepithelial neoplasia 
3 (PanIN-3), intraductal papillary mucinous neoplasia (IPMN) with high-grade dysplasia and pancreatic 
neuroendocrine tumours (PanNET) equal to or greater than 2 cm in diameter. 
Results 
Of 76 high risk individuals identified in 11 surveillance programmes; 71 had undergone surgery and 5 
had been diagnosed with inoperable PDAC. Of the 71 resections 32 (45%) had PDAC or a high-risk 
precursor (19 PDAC, 4 main duct IPMN, 4 branch duct IPMN, 5 PanIN-3; the other 39 patients had 
lesions thought to be associated with lower risks of neoplastic progression. Age ≥65, female gender, 
carriage of a gene mutation and location of a lesion in the head/uncinate region were associated with 
high-risk precursor lesions or PDAC. The survival of high risk individuals with low-risk neoplastic lesions 
versus those with high-risk precursor lesions did not differ. Survival was worse among patients with 
PDAC. There was no surgery-related mortality. 
Conclusion 
A high proportion of high risk individuals who underwent surgical resection for screen or surveillance-
detected pancreatic lesions had a high risk neoplastic precursor lesion or PDAC at the time of surgery. 
Survival was better in high risk individuals who had either low or high-risk neoplastic precursor lesions 
compared to those who had developed PDAC.  
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Despite improvements in treatments  for PDAC, it remains the third leading cause of cancer deaths in 
the United States (U.S.) with a 5-year survival of only 8% 1. By 2030, PDAC is projected to become the 
second leading cause of cancer-related death in that country. 2. Advances in screening, prevention, and 
treatment have the potential to change pancreatic cancer incidence and death rates 2. Inherited 
susceptibility is thought to be a major factor in the development of PDAC, accounting for 5-10% of cases 
3. Surveillance for PDAC and its precursor lesions in asymptomatic high-risk individuals is increasingly 
being performed worldwide 4-15.  These high-risk individuals can be categorized into two groups: carriers 
of known PDAC-associated gene mutations (especially carriers of deleterious mutations in CKDN2A, 
BRCA2, BRCA1, ATM, TP53, PRSS1 or STK11), and  first-degree relatives in familial PDAC  (clustering of at 
least two first-degree blood relatives with PDAC) 16. The goals of surveillance have been previously 
described by the CAncer of the Pancreas Screening (CAPS) Consortium 17. These include the detection 
and treatment of early invasive pancreatic cancer (T1N0M0) at baseline or follow-up; detection and 
treatment of any invasive resectable cancer at baseline screening; detection and treatment of multifocal 
pancreatic intraepithelial neoplasia 3 (PanIN-3); and the detection and treatment of intraductal papillary 
mucinous neoplasia (IPMN) with high-grade dysplasia.  
 Few studies have described the surgical pathology findings in high-risk patients who have 
undergone surgery 15 18. The CAPS Consortium Registry was created to gather information rapidly about 
the experience of surveillance. In this study, we evaluated the diagnostic yield and outcomes of high-risk 
individuals who underwent surgical resection or progressed to invasive cancer and examined the 
characteristics of patients who developed high-risk neoplastic precursor lesions or PDAC.  





All participating centres in the CAPS Consortium (36 centres, 9 countries) were requested to enter 
patient information data for high-risk individuals participating in their PDAC-surveillance programmes 
who  had either undergone  pancreatic surgery because of the detection of a suspicious pancreatic 
lesion, or who had progressed to advanced non-resectable malignant disease. Data were collected 
through the use of web-based software (OmniComm™ Electronic Data Capture). Anonymized clinical 
and demographic information was collected relating to gender, age, tobacco and alcohol use, diabetes 
mellitus, history of pancreatitis, body mass index (BMI), known gene mutations, and family history of 
PDAC. In addition, pancreatic imaging modalities that detected the lesions, characteristics of the lesions 
detected by imaging, timing of detection, therapy, pathology and outcomes after surgery or diagnosis of 
advanced PDAC were also recorded. Research protocols of all participating centres were largely based 
on the consensus statements of the Cancer of the Pancreas Screening (CAPS) Consortium produced in 
2013 17, acknowledging that the  nature of this study and its time span made it inevitable that 
differences between protocols of screening centres would exist.. The index examinations and follow-up 
examinations were carried out using MRI and/or endoscopic ultrasonography. However, when suspect 
lesions were detected, other modalities, such as CT imaging, were often used for further 
characterization and staging. All individuals in this study provided written informed consent for their 
participation in the respective PDAC surveillance programmes as approved by the Ethical Committees of 
the participating centres and the study was conducted in accordance with the Declaration of Helsinki.  
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Participants with pathologically proven high-risk neoplastic precursor lesions or pathologically 
proven PDAC were compared to participants who underwent surgery but in whom the resection 
specimen harboured no high-risk precursor lesion or PDAC. HRN were defined as uni- or multifocal 
PanIN-3 lesions, main and branch-duct duct IPMNs with high-grade dysplasia and PanNETs ≥ 2 cm 19 20.  
Statistical methods 
Descriptive statistics were used to characterize patient and lesion characteristics. Univariable analyses 
(Chi square, or Fisher’s exact test where indicated) were performed on possible risk factors associated 
with PDAC or high-risk neoplasia precursor lesions. All variables with a P-value <0.200 in the univariable 
analyses were included in the multivariable analysis. Survival comparisons for different subgroups were 
plotted as Kaplan-Meier curves and hazard ratios calculated using Log Rank. All analyses were conducted 




A total of 76 high risk individuals were included from 11 PDAC-surveillance programmes in 4 
countries (United States, The Netherlands, Israel, Italy). Between the 11 centres, some 1700 patients 
considered to be at high-risk underwent surveillance, of whom approximately 70% were female, Of the 
76 included with precursor lesions, 5 were diagnosed with advanced disease during surveillance and 71 
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underwent surgery for a suspected lesion of whom two were discovered to have inoperable disease. 
Baseline characteristics of all 76 high-risk individuals are summarized in Table 1.  
High-risk neoplastic precursor lesions and (advanced) pancreatic ductal adenocarcinoma 
High-risk neoplastic precursor lesions or  PDAC were present in the surgical specimens of 32 
(45%) of the 71 patients  who underwent surgery:. Among these, five (7%) patients had PanIN-3 lesions 
as the highest grade neoplastic lesion, four (6%) a branch-duct IPMN with high-grade dysplasia, four 
(6%) a main-duct IPMN, and 19 (27%) had PDAC. Pathology findings in all 71 high risk individuals who 
underwent surgery are summarized in Table 2, as well as lesion characteristics and type of surgery.  
In 39 high-risk individuals, (55%) the indication for surgery was detected at their baseline 
screening evaluation. Of the remaining 32 (45%) patients, lesions were detected at follow-up 
investigations. In 9 of these 32 patients, a lesion was already present at previous investigations, for a 
mean time of 9 months prior to resection. These lesions initially did not meet resection criteria, but a 
changing appearance with time led to resection. In 10 of  these 32 patients, there were  mean  delays of 
7 months from their recommended screening interval (recommended screening intervals ranged from 3-
24 months, depending on  visualization and type of lesion). EUS detected the vast majority of lesions 
(87.3%). A total of 93 suspicious lesions were detected in the 71 patients who underwent surgery, of 
which 44 (47%) were cystic and 33 (36%) solid in appearance. Mean size of these 93 lesions was 14 mm, 
ranging between 3 to 51 mm.  
Distal pancreatectomy was performed in 36 patients (51%) and a pancreaticoduodenectomy in 
18 (25%). Complications of surgery were seen in 34 (48%) patients. The most common complications 
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were infection (14%), delayed gastric emptying (9%) and pancreatic fistula (6%). There were no 
surveillance or surgery-related deaths. 
Of the five patients diagnosed with advanced disease during surveillance, three (60%) were 
identified at follow-up, the other two were detected at baseline evaluation.   
Outcomes 
The outcomes of both risk groups are summarized in Table 3. Of all 76 included patients, 61 
(80%) are still alive, a mean 52 months after surgery or diagnosis of PDAC. Of 71 (83%) high risk 
individuals who underwent surgery 59 are still alive after surgery after a mean follow up of 54 months.  
Of the 12 patients who have died, 8 deaths were PDAC-related. Survival was significantly poorer for 
individuals with advanced PDAC as compared to the individuals who underwent surgery (survival 40% vs 
83%, P=0.05; mean 10 vs 54 months, P <0.001). Only 2 (3%) of 71 high risk patients who underwent 
surgery died within a year (all-cause 1-year mortality),  compared to 2 of 5 with advanced PDAC; 52% 
survived more than 3 years after surgery.  
Risk factors  
Univariable analyses for factors associated with high-risk neoplastic precursor lesions or PDAC in 
the resection specimen (see Table 4) included age ≥ 65 at the time of surgery (OR 4.1, P = 0.007) and 
female gender (OR 3.8, P = 0.007). In the multivariable analysis, four factors were significantly associated 
with the presence of a high-risk precursor lesion or PDAC in the pancreatic resection specimen: age ≥ 65 
at the time of surgery (OR 7.5, P = 0.010), female gender (OR 5.8, P = 0.017), carriage of a deleterious 
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mutation in a known pancreatic cancer susceptibility gene (OR 4.9, P = 0.040) and location of a lesion in 
the head/uncinate region of the pancreas (OR 4.2, P = 0.041).  
Survival analysis 
The pancreatic neoplasia grade was significantly associated with overall survival in high-risk 
individuals. Figure 1 shows the Kaplan-Meier curve for different pathologic subgroups. High-risk 
individuals with no or low-risk neoplastic lesions (group A, 39) and high-risk individuals with high-risk 
neoplastic precursor lesions (group B, 13) had the best survival, followed by those with stage I or II PDAC 
(group C, 16), and those with stage III or IV PDAC (group D, 8). The hazard ratio for group B compared to 
group A was 4.5 (P = 0.163), compared to group C, 13.1 (P = <0.001), and compared to  group D, 25.3 (P 
= <0.001).  
 
DISCUSSION 
In this multicentre international study, high-risk neoplastic lesions or PDAC were present in 45% 
of the high-risk population that underwent surgery in a PDAC-surveillance programme. Survival between 
high-risk patients with no or low-risk lesions versus those with high-risk neoplastic precursor lesions- did 
not differ significantly. The patients who developed PDAC had a significantly higher overall mortality and 
poorer survival  compared to those with no or low-risk neoplastic lesions.  
 Surveillance of high-risk individuals has the potential to improve the poor survival of PDAC and is 
increasingly being undertaken. In 2010, the CAPS Consortium was formed to help organize global 
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pancreatic surveillance. By pooling data from participating centres, important research questions 
pertaining to pancreatic surveillance can be assessed readily. The present analysis reports the pooled 
data of high-risk individuals for whom surveillance led to the detection of advanced disease or a lesion 
for which pancreatic surgery was performed.    
 Goals of surveillance previously described by the CAPS Consortium 17 were early invasive cancers 
(T1N0M0), PanIN-3, main duct IPMNs and branch duct IPMNs with high-grade dysplasia. While PanNETs 
≥ 2 cm were also included in the definition no such large PanNETs were detected. Timing of intervention 
is an important issue. In this series, 55% of the resection specimens harboured no high-risk neoplastic 
precursor lesion or PDAC, but did contain, for example, low-risk PanIN lesions (PanIN-1 or 2) or small 
PanNETs. Only long-term follow-up will disclose whether patients with resected low-risk lesions might 
have a reduced risk of subsequently developing PDAC. For some patients, surgical resection was 
performed too late, as only 3 of the 19 PDACs were T1. The main challenge in any surveillance 
programme is how to distinguish between those individuals that can be safely monitored and those who 
require surgery to resect a neoplastic lesion at a curable stage. 
 In this study, 55% of lesions that prompted surgery were detected at a baseline visit. This could 
raise the question whether one-time screening of high-risk individuals at a given age is also effective. 
Alternatively, when an advanced lesion is found at the index investigation, it could be argued that this 
lesion might have been detected at an earlier stage with potentially a better outcome if surveillance had 
started at an earlier age. As new lesions were detected  in several patients who missed their follow-up 
visit by only a few months, it seems appropriate to adhere to an annual surveillance protocol, until more 
data are available from large prospective cohorts. 
This article is protected by copyright. All rights reserved.
11 
 
 Although not all patients with main-duct IPMN progress to cancer, the overall 10-year risk is 
estimated at approximately 25% 21. Only 2 patients in the present study were identified with these 
lesions prior to surgery. After pathological evaluation of the resection specimen 4 cystic lesions were re-
classified as main-duct IPMN. Discrepancy between imaging and pathology is not an uncommon finding 
in this situation 22.  
 The present study also sought to identify looked for risk factors that can easily be assessed 
preoperatively for association with high-risk neoplastic precursor lesions or PDAC in the resection 
specimens. Multivariable analyses showed age ≥ 65, female gender, carriage of a gene mutation and 
location of a lesion in the head/uncinate region of the pancreas to be associated with the detection of a 
high-risk precursor lesion or PDAC in the resection specimen. Among female carriers of a gene mutation 
aged above 65 with a lesion suspicious for malignancy in the head/uncinate region of the pancreas, one 
should carefully weigh the option of pancreatic surgery versus continuing surveillance.     
 Survival analysis indicated that this was strongly influenced by  the stage of disease at diagnosis 
23. Importantly, the survival of patients with high-risk neoplastic precursors in their resection specimen 
was equal to  those  with no or low-risk neoplastic lesions, emphasizing the need to reliably identify 
high-risk precursor lesions more than early cancers.  
 The strength of this study is the international pooling of data on PDAC-surveillance programmes. 
This yielded a unique and sizeable cohort of high-risk patients participating in PDAC-surveillance 
programmes in whom either a suspicious lesion was detected for which they underwent surgery, or in 
whom an inoperable pancreatic cancer developed. The main limitations of this study are its design and 
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potential lead-time and length bias 24. Another limitation is that differences between protocols of the 
centres existed, particularly before publication of consensus statements of the Cancer of the Pancreas 
Screening (CAPS) Consortium in 2013 17. Although this is the largest cohort described, its sample size is 
still too limited to assess differences in survival between R0 and R1 resections. Another limitation is the 
lack of detailed information of all 1700 high-risk individuals who underwent surveillance. Attention was 
specifically focused on the highly selected group who either developed advanced neoplasia or 
underwent pancreatic surgery and this study has added new, interesting and valuable data to the 
literature that provides some rationale to screening individuals at high risk for pancreatic cancer. More 
research is needed to better understand the risk factors for individuals at high risk of developing PDAC, 
and  improve the selection of high-risk individuals for surgery. Collaborating internationally in large 
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Table 1. Baseline characteristics of all high-risk individuals who underwent surgery due to the detection 
of a suspicious pancreatic lesion or who were diagnosed with advanced pancreatic cancer during 
participation in PDAC surveillance. 
 




High-risk individuals who 




Age at surgery or diagnosis of advanced PDAC, mean 
(median, range, SD) 60.3 (59.8, 36-80, 11.6) 70.5 (65-80, 6.6) 
Gender, male 37 (52.1%) 1 (20.0%) 
Race 
   White 
   Black 










   Familial pancreatic cancer (FPC) 
   CDKN2A (FAMMM syndrome) 
   BRCA2 (HBOC)    
   Peutz-Jeghers syndrome    
   BRCA1 (HBOC) 
   TP53 (Li Fraumeni syndrome) 
   MMR (Lynch syndrome) 
   APC  
   ATM 























Number of FDR with PDAC, mean (median, range, SD) 
Number of SDR with PDAC, mean (median, range, SD) 
1.5 (1.0, 0-3, 0.8) 
1.1 (1.0, 0-4, 1.0) 
1.4 (0-2, 0.9) 
0.3 (0-1, 0.6) 
Youngest family member affected by PDAC,   mean 
(range, SD) 55.5 (33-77, 10.8) 63.3 (52-68, 7.5) 
Body mass index, mean (median, range, SD) 27.3 (26.6, 18-48, 5.1) 26.1 (23-31, 3.7) 
Personal history of diabetes 11 (15.5%) 2 (40.0%) 
Number of months of diabetes prior to surgery or 
diagnosis of advanced PDAC, mean (median, range, SD) 36.6 (45.0, 0-63, 23.7) 66 (12-120, 76.4) 
Personal history of pancreatitis 9 (12.7%) 1 (20.0%) 
Smoking behavior 
   Never smoker  
   Former smoker 
   Current smoker 
   No data 
   ≥ 10 pack years in total 
















   Never consumer  
   Former consumer 
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   No data 
   ≥ 10 units per week (current or past) 







PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation; FAMMM, familial atypical multiple mole 
melanoma syndrome; HBOC, hereditary breast and ovarian cancer; MMR, mismatch repair genes; APC, 
adenomatous polyposis coli; ATM, ataxia telangiectasia mutated; FDR, first degree relative; SDR, second degree 
relative. 
Table 2. Overview of lesion characteristics, type of surgery and pathology in all high-risk individuals who 
underwent surgery (n=71) and all high-risk individuals who were diagnosed with advanced disease (n=5) while 
















   Time point of lesion detection: 
        Baseline 
        Follow-up 
             Present at previous investigations 
             Mean months of lesion visualization prior to resection/diagnosis 
(median, range, SD) 
             Case overdue for recommended screening 
             Mean months overdue for recommended screening (median, 
range, SD) 
   Modality that detected the lesion (≥1 option possible): 
        EUS 
        MRI/MRCP 
        CT / PET-CT 
        ERCP 
   Lesion type of lesions that were reason for surgery (n=93) 
        Cystic  
        Solid                 
        Hypoechoic 
        Dilated pancreatic duct 
        Features of chronic pancreatitis 
        Other 
   Lesion location (n=93) 
        Head/uncinate region 
        Body 
        Tail 
        No data 






8.7 (5.0, 1-32, 9.5) 
 
10 (14.1%) 

























41 (41, 41, -) 
 
1 (20.0%) 
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        All lesions (n=93) 
        Cystic lesions (n=44) 
        Solid lesions (n=33) 
14.0 (11.9, 3-51, 8.8) 
13.6 (11.6, 3-40, 8.0) 
15.5 (13.0, 4-51, 10.0) 
Neoadjuvant therapy 4 (5.6%) N/A 
Type of surgery 
   Distal pancreatectomy 
   Pancreaticoduodenectomy 
   Total pancreatectomy 
   Pancreaticoduodenectomy followed by completion pancreatectomy 
   Central pancreatectomy 









Complications of surgery (≥1 option possible) 
   None 
   Infectious complications 
   Delayed gastric emptying 
   Pancreatic fistula 
   Bile leak 
   Peri-pancreatic fluid collection 
   Other 











Pathology (≥1 could be present) 
   PDAC 
   Main-duct IPMN with high-grade dysplasia 
   Main-duct IPMN with moderate-grade dysplasia 
   Main-duct IPMN with low-grade dysplasia 
   Mixed-duct IPMN with high-grade dysplasia 
   Mixed-duct IPMN with moderate-grade dysplasia 
   Mixed-duct IPMN with low-grade dysplasia 
   Branch-duct IPMN with high-grade dysplasia 
   Branch-duct IPMN with moderate-grade dysplasia 
   Branch-duct IPMN with low-grade dysplasia 
   PanIN-3, multifocal 
   PanIN-3, unifocal 
   PanIN-2, multifocal 
   PanIN-2, unifocal 
   PanIN-1, multifocal 
   PanIN-1, unifocal 
   Pancreatic neuroendocrine tumor ≥ 2 cm 
   Pancreatic neuroendocrine tumor < 2 cm 
   Incipient IPMN 
   Serous cystadenoma 












































Highest grade of neoplastic lesion per HRI 
   PDAC 
      Stage I/II PDAC 
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   Main-duct IPMN with high-grade dysplasia 
   Main-duct IPMN with moderate-grade dysplasia 
   Main-duct IPMN with low-grade dysplasia 
   Branch-duct IPMN with high-grade dysplasia 
   Branch-duct IPMN with moderate-grade dysplasia 
   Branch-duct IPMN with low-grade dysplasia 
   PanIN-3, multifocal 
   PanIN-3, unifocal 
   PanIN-2, multifocal 
   PanIN-2, unifocal 
   PanIN-1, multifocal 
   PanIN-1, unifocal  
   Pancreatic neuroendocrine tumor < 2 cm 





























PDAC, pancreatic ductal adenocarcinoma; EUS, endoscopic ultrasonography; MRI, magnetic resonance imaging; 
CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; IPMN, intraductal papillary 
mucinous neoplasm; PanIN, pancreatic intraepithelial neoplasia; N/A, not applicable. 
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Table 3. Outcomes in all high-risk individuals who underwent surgery (n=71) and all high-risk individuals who were 
diagnosed with advanced disease (n=5) while participating in pancreatic cancer surveillance 
 






who were diagnosed 




Follow-up time in mean months (median, range, SD) 51.6 (42.0, 0-168, 45.1) 8.2 (3.0, 3-28, 11.1) < 0.001 
Survival 
   Alive 
   Mean months after surgery/diagnosis (median, range, SD) 
   Long-term survival (≥ 3 years) 
 
59 (83.1%) 











   Died 
   Mean months after surgery/diagnosis (median, range, SD) 
   Short-term mortality (≤ 1 year) 
   PDAC-related  
   Non-PDAC-related 
   Unknown cause of death 
 
12 (16.9%) 

















PDAC, pancreatic ductal adenocarcinoma; SD, standard deviation 
Bold P-values were considered statistically significant 
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Table 4. Univariate and multivariate analyses for factors possibly associated with high-risk neoplastic precursor 
lesions or pancreatic ductal adenocarcinoma in the resection specimen 
 
Factors Univariate analyses Multivariate analyses 
 Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value 
Age ≥65 at time of surgery 4.108 (1.4-11.7) 0.007 7.530 (1.6-35.0) 0.010 
Female gender 3.818 (1.4-10.3) 0.007 5.776 (1.4-24.3) 0.017 
White race 0.254 (0.0-2.6) 0.321   
Carrier of a gene mutation 2.395 (0.8-7.2) 0.113 4.918 (1.1-22.6) 0.040 
≥2 first-degree relatives affected by PDAC 2.400 (0.9-6.4) 0.076 1.712 (0.4-7.2) 0.462 
Family member <50 affected by PDAC 1.150 (0.3-3.8) 0.820   
Body Mass Index ≥25 0.570 (0.2-1.7) 0.303   
Personal history of diabetes 1.829 (0.5-6.8) 0.505   
Personal history of pancreatitis 0.686 (0.2-3.0) 0.727   
Current or former smoker 1.000 (0.4-2.7) 1.000   
>10 pack years of smoking  0.952 (0.1-6.3) 1.000   
Current or former alcohol consumer 0.702 (0.3-1.8) 0.470   
Detection of lesion at follow-up visit 1.142 (0.4-2.9) 0.782   
Solid lesion type (vs cystic lesion) 1.111 (0.4-3.1) 0.839   
Location of lesion in the head/uncinate 
region (vs location in body/tail) 2.333 (0.8-6.6) 0.105 4.232 (1.1-16.9) 0.041 
Lesion size ≥1 centimeter 1.260 (0.4-4.1) 0.702   
Surgery after 2011 1.473 (0.5-4.0) 0.448   
OR, odds ratio; CI, confidence interval; PDAC, pancreatic ductal adenocarcinoma. 
Bold P-values were considered statistically significant 
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Figure 1. Kaplan-Meier survival curve per subgroup 
(Figure attached separately)  
Legend: 
A. Low-risk neoplastic lesions including pancreatic neuroendocrine tumors (PanNETs) <2 cm (n=39) 
B. High-risk neoplastic lesions including all main-duct intraductal papillary mucinous neoplasms (IPMNs), 
branch-duct IPMNs with high-grade dysplasia and PanIN-3 lesions (n=13) 
C. Stage I and II PDACs (n=16) 
D. Stage III and IV PDACs (n=8)  




On behalf of the participating centers of the CAncer of the Pancreas Screening (CAPS) Consortium (in 
alphabetical order): 
Amsterdam Medical Center (The Netherlands), Beaujon Hospital (France), Columbia University Medical 
Center (USA), Creighton University Hereditary Cancer Center (USA), Dana Farber Cancer Institute (USA), 
Erasmus MC University Medical Center Rotterdam (The Netherlands), Icahn School of Medicine at Mount 
Sinai (USA), Indiana University (USA), Institut Paoli-Calmettes (France), Jefferson Medical Center (USA), 
Johns Hopkins Medical Institutions (USA), Mayo Clinic (USA), MD Anderson Cancer Center (USA), Medical 
College of Wisconsin (USA), Karolinska Institute (Sweden), Kyoto University Hospital (Japan), Ohio State 
University (USA), Pancreatic Cancer Action Network (USA), Rambam Healthcare Campus (Israel), St. 
Vincent’s Hospital (Australia), Teikyo University Medical Center (Japan), University Hospital of Verona 
(Italy), University Hospital of Santiago de Compostela (Spain), University Hospitals Case Medical Center 
(USA), University of Alabama (USA), University of Arizona (USA), University of California San Diego (USA), 
University of Colorado Denver (USA), University of Michigan (USA), University of Nebraska (USA), 
University of Pennsylvania (USA), University of Pittsburgh (USA), University of Southern California (USA), 
Yale University (USA), Vita-Salute San Raffaele University (Italy), Washington University (USA) 
 
Foot note 
No preregistration exists for the reported studies reported in this article 
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